Bayer Aktiengesellschaft (BAYN) Earnings Call Transcript & Summary

August 4, 2020

Deutsche Boerse Xetra DE Health Care Pharmaceuticals earnings 68 min

Earnings Call Speaker Segments

Operator

operator
#1

Good day, everyone, and thanks for joining us. This is Bayer's Investor and Analyst Conference Call covering the second quarter 2020 results, and you're all welcome here. During the recorded presentation today, every participant will be in listen-only mode. After the presentation, there will be a question and answer session. Should anyone have trouble hearing the conference, just press the star key and then zero on your telephone, and an operator will assist you. At this point, I'd like to hand the conference over to Mr. Oliver Maier, Head of Investor Relations at Bayer AG. Sir, the floor is yours.

Oliver Maier

executive
#2

Thanks, Emma. Good afternoon, and thank you for being with us today for the earnings conference call covering our second quarter 2020. Joining me are Werner Baumann, our CEO, and Wolfgang Nickl, our CFO. The businesses are represented by the responsible management board members, who are also on the line. For Crop Science, we have Liam Condon. For Pharma, we have Stefan Oelrich, and for Consumer Health, we have Heiko Schipper. Werner will start today's call with an overview of key events in this quarter, our group financial performance, and how the divisions performed. Wolfgang will then present a deep dive into the financials of the second quarter, the outlook in our key focus areas for the remainder of the year before we open up with the Q&A session. As always, I would like to start by drawing your attention to the cautionary language that is included in our safe harbor statement, as well as in all the materials that we have distributed today. With that, I'll hand it over to you, Werner.

Werner Baumann

executive
#3

Okay. Thank you, Oliver, and good afternoon, everyone. I'm glad to have you join our conference call today. I'll begin with the topic that is obviously foremost on people's minds and give you a brief update on litigation. On June 24th, we disclosed a set of agreements aimed at resolving the major outstanding Monsanto litigation concerning U.S. Roundup, product liability, dicamba drift, and the majority of PCB water cases. Among these three, the most important is, naturally, the agreements to settle the bulk of the current Roundup litigation and to establish a mechanism for managing and resolving possible claims in the future. Let me repeat that Bayer stays firmly dedicated to a resolution that tackles both the existing Roundup litigation and potential future litigation at the same time. As many of you are aware, we estimated the total costs needed to cover all 125,000 current cases, including an allowance for resolving plaintiffs with whom no agreement has yet been reached, at as much as $9.6 billion US. As we stated in June, we intended to address potential future Roundup litigation by means of a separate class agreement between Monsanto and plaintiffs' counsel, which, of course, had the support of the court-appointed mediator, Ken Feinberg. The proposal that was submitted to Judge Chhabria for approval contained an additional payment of $1.25 billion US.

Werner Baumann

executive
#4

Once the judge voiced concerns regarding particular elements of the agreement, the parties chose to pull their motion so that the court's questions could be addressed in a comprehensive way. We are continuing to work toward resolving the court's concerns as swiftly as we can. Because so many parties are involved and the matters under discussion are so complex, we are unable at this point in time to give an estimate of the timetable for returning to the court. Moving on to the appeals: the Johnson case is among the three Roundup cases that have proceeded to trial and that do continue to work their way through the appeals process. The appellate court recently ruled to cut the compensatory and punitive damages in this case yet further. Although we view that as a step in the right direction, our belief remains that the jury's verdict and damage awards are inconsistent with the evidence at trial and the law. We will weigh our legal options, including filing an appeal with the Supreme Court of California. Today, a motion for reconsideration will be filed with the Court of Appeal of the State of California, which is a necessary step before a state Supreme Court appeal. We continue to stand strongly behind the safety and utility of Roundup, a position supported by, for decades of extensive science and favorable assessments by leading health regulators around the world.

Werner Baumann

executive
#5

On the other big unresolved legal matters, we've continued to make headway in talks to settle the Essure case — that's the permanent birth control device. Conversations with the plaintiffs' attorneys have picked up pace over the last few weeks. So in quarter 2 we booked provisions where it made sense. Let me be clear: nothing has been signed, and this provision hasn't involved any payments so far. We'll share more on that topic once a formal resolution is reached, if and when that happens. I'd also like to address COVID-19, which is still impacting our company's workforce and, in fact, how we operate. Throughout the coronavirus pandemic, our top priority has stayed the same: safeguarding employees' safety and well-being and at the same time keeping the business running. Drawing on our know-how in health and nutrition, we're helping the worldwide effort against COVID-19, in line with our vision of Health for All and Hunger for None. Even though progress has been achieved and we're all still learning an enormous amount about the virus, the coronavirus pandemic is nowhere near finished. In fact, we're selectively tightening our safety protocols, which is a sensible step given the recent rises in infection rates seen in many countries as governments loosen their restrictions.

Werner Baumann

executive
#6

Keeping hospitals, physicians, patients, consumers, and farmers reliably supplied with our products and services has been our clear priority. In addition to that, we recently disclosed our participation in the AMR Action Fund, which is meant to tackle the swift growth of antibiotic-resistant infections. This kind of research collaboration reflects the foresight needed should other global challenges arise down the road. Before going further, it is worth restating yesterday's news about the successful divestment of our animal health business to Elanco. That divestment is the final, and in fact biggest, transaction among the portfolio measures outlined at the 2018 capital markets day. With that as a strong backdrop, I would now like to provide an update on how our group and divisions performed in the second quarter. Considering how the pandemic has unfolded, its effect is more pronounced this quarter than it was in the prior one. Although sales slipped slightly to EUR 10.1 billion, a 3% currency and portfolio-adjusted reduction, EBITDA before special items climbed by 6% to EUR 2.9 billion. Core EPS for us increased by 5% compared with the prior year, arriving at EUR 1.59, and free cash flow sits at EUR 1.402 billion, versus EUR 751 million in quarter two of last year.

Werner Baumann

executive
#7

If we broaden the view to the first half of 2020, smoothing out some of the stockpiling and phasing effects, the group has delivered solid results despite headwinds stemming from the COVID-19 situation, which hit our Pharmaceuticals Division especially hard in the first half of the year. Sales were up 2% to EUR 22.9 billion, EBITDA before special items climbed 8% to EUR 7.3 billion, and core EPS increased 8% to EUR 4.26. I want to emphasize that safeguarding our bottom line through prudent cost management and accelerated contributions from our efficiency programs, along with a strong focus on cash flow, continues to be of utmost importance to us. Now let me comment on our outlook. On the last investor call, we discussed the most relevant COVID-19 related variables that we expected to affect our business, since a solid assessment for 2020 was not yet possible. Let me add that this obviously also applies to our midterm guidance, which evidently also came before the pandemic. The impacts we are seeing are more pronounced and likely also deeper, and they will take longer than most of us would have thought. We also see that currency developments are heavily affected by the coronavirus crisis.

Werner Baumann

executive
#8

Wolfgang is going to walk you through an update on those variables and how they affect our full year 2020 guidance financially. Now I'll move on to how each of our divisions performed, beginning with Crop Science. We posted 3% growth in sales on a currency- and portfolio-adjusted basis, and that growth was led by the Americas and APAC. In Latin America, we recorded gains in corn, especially in Brazil, and also in insecticides and herbicides, all on the back of higher volumes. Fox Xpro fungicide kept advancing in Latin America, where we additionally gained from stronger penetration of the Intacta Roundup Ready 2 PRO trait in our soybean business. Growth in APAC was fueled by fungicide and insecticide sales, whereas in Europe, buying of crop protection during the earlier quarter resulted in lower sales of herbicides, fungicides, and insecticides. Turning to North America, we enjoyed solid growth in soybeans, helped by an expected rise in acreage compared with the prior year and by demand shifting out of the first quarter as growers postponed their decisions. On top of that, our Roundup Ready Xtend footprint faced a highly competitive market, with an estimated 50 million traited acres this season, counting both branded and licensed acres. Our herbicide and fungicide business in North America also grew, thanks to normalized weather and the success of the Bayer PLUS program, while North American corn sales reached a higher level year over year despite only a modest gain in planted acres and anticipated share gains stemming from demand moving into earlier quarters.

Werner Baumann

executive
#9

We're also happy to report that with Climate FieldView we've surpassed our target of 110 million subscribed acres, as growers keep adopting digital technology to boost their productivity and profitability. Looking at earnings, Crop Science lifted its EBITDA before special items by 28% to EUR 1.4 billion. That gain came from higher volumes, ongoing cost discipline, and cost synergies stemming from integrating our acquired business, along with the timing of certain return provisions in Brazil. Also, earlier this month we launched a new program, the Bayer Carbon Initiative. Through it, growers will be rewarded for producing carbon credits by using climate-smart agronomic practices, which in essence opens up a new revenue stream on the farm. We're the first company to build a transparent, science-based, and collaborative approach to agriculture's carbon market, and we look forward to updating you as the program develops. Let's move to pharma now. Pharmaceutical sales fell 9% on a currency- and portfolio-adjusted basis to EUR 4 billion in the second quarter. The drop was mainly due to fewer elective treatments stemming from the COVID-19 situation and to lower prices from implementing the second round of volume-based procurement in China.

Werner Baumann

executive
#10

Part of that was offset by Xarelto, our top-selling product, which kept up its solid growth path with a 7% increase. During the first half of 2020, Xarelto posted a sales gain of 13%, which confirms the projection of low teens percentage growth for the entire year. COVID-19 hit our intrauterine device franchise especially hard, with sales falling 37%, along with our radiology products, which dropped 21%, and EYLEA, which declined 6%. Where EYLEA is concerned, the adverse impact from volume reductions caused by COVID-19 and price cuts in Japan was partly offset by phasing effects in Japan moving from quarter one into quarter two and by the prefilled syringe launch. In the first half of 2020, EYLEA sales were down 3%. An improvement in the situation is expected during the second half of the year, and full year sales are now projected to stay at the prior year level. The adverse price effect this quarter came largely from volume-based procurement for Glucobay and Avelox in China. Although we took part successfully in the tenders for both products, we had to accept substantial price concessions. For Glucobay, solid volume gains partly offset the adverse price impact. Even with the substantial sales decline and the associated gross margin loss this quarter, we kept the effect on EBITDA before special items at pharma to 7% and delivered EUR 1.4 billion in EBITDA before special items.

Werner Baumann

executive
#11

Careful expense control, including reduced marketing spend and a reallocation of research and development costs stemming from COVID-19, helped safeguard our bottom line. Turning to our R&D work, we've also achieved some solid progress of late. For vericiguat, we filed marketing authorization applications in Europe and Japan seeking approval to treat chronic heart failure. We were likewise encouraged that the FDA granted priority review to the new drug application for vericiguat. Several weeks back, our FIDELIO Diabetic Kidney Disease study, which assesses how efficacious and safe finerenone is in patients suffering from chronic kidney disease alongside type 2 diabetes, hit its primary endpoint. The clinical data are going to be presented at a scientific meeting scheduled soon. Beyond that, they have broadened the clinical development program for finerenone by adding a phase III trial involving patients who have heart failure with preserved ejection fraction. We additionally shared compelling overall survival data for Nubeqa, our novel medication for treating prostate cancer. Among men with non-metastatic castration-resistant prostate cancer, Nubeqa cut the risk of death by 31% in a significant way. These findings build on the positive phase III results published earlier and underscore NUBEQA's strong competitive profile. Through strategic portfolio additions and in-licensing, we keep pursuing external growth opportunities.

Werner Baumann

executive
#12

Now I’ll move to Consumer Health to wrap up the divisional updates. Following a very strong first quarter, sales fell 2% in the second quarter after an anticipated trade inventory adjustment and a store-traffic slowdown caused by COVID-19-related quarantine measures in most countries. Offsetting those phasing effects, Consumer Health had a strong first half, with 6% growth on a currency- and portfolio-adjusted basis. Nutritionals posted an exceptionally strong growth trajectory, including in the second quarter, rising 14% on improved consumption trends, while Allergy and Cold had the steepest decline, at 17%, because of the COVID-19-related effects I just mentioned. Regionally, Europe saw lower sales in Digestive Health, Dermatology, and Allergy and Cold, largely because of the inventory build-up in the prior quarter that I noted earlier. In North America, sales were level with the prior year. Strong Nutritionals growth was offset by declines in Allergy and Cold. Sales in Asia Pacific and particularly Latin America rose on strong demand for Dermatology and Nutritionals. On earnings, our EBITDA margin before special items rose to 21.1% in the second quarter, up 130 basis points from the previous quarter.

Werner Baumann

executive
#13

That 11% drop in EBITDA before special items largely reflects the fact that our divested businesses no longer contribute. Strip out that portfolio effect, and EBITDA before special items would sit at the prior year level, as underlying operational improvements were offset by unfavorable currency developments. All in all, we're glad to see the turnaround plan for Consumer Health fully on track. With that, I'll hand it to you, Wolfgang, to expand on our financial results and the outlook.

Wolfgang Nickl

executive
#14

Thank you, Werner. Good morning, everyone — a warm welcome from my side as well. I'll take you through a few more financial specifics for Q2, and after that I'll discuss how the business is performing and what we expect for the whole year. Sales as reported fell 6% in the second quarter, to EUR 10.1 billion. The underlying picture was a bit better: once you strip out currency and portfolio effects, group sales were down 3%. Group EBITDA before special items reached EUR 2.9 billion, 6% higher than a year earlier, and the EBITDA margin rose 320 basis points to 28.7%. Tight cost control, faster efficiency programs and a lower provision for variable compensation all helped lift earnings even though sales dipped slightly. Compared with last year, foreign exchange movements weighed on sales by EUR 214 million. The hit to EBITDA was EUR 12 million. Core earnings per share for the second quarter rose 5% from a year ago, reaching EUR 1.59. Crop Science contributed more to that gain than any other business. Our core tax rate was 23% this quarter, versus 21% in the second quarter of last year, which meant higher tax expenses.

Wolfgang Nickl

executive
#15

The core financial result showed a modest improvement, moving from -EUR 402 million to -EUR 342 million, driven primarily by changes in the fair value of debt instruments. And lastly, our free cash flow rose from EUR 751 million to EUR 1.4 billion versus the prior year. Strong collections, the timing of incentive payouts for last year, and lower tax payments than the previous year were the main drivers. Those prior year tax payments were tied to the asset sale to BASF. Our core earnings per share rose by EUR 0.08 in the second quarter year-on-year, while reported EPS fell from a gain of EUR 0.41 to a reported loss of EUR 9.72. As we typically do, we adjusted for acquisition-related amortization, special items in the financial results tied to the fair value of the Covestro shares, and the contribution from our discontinued business. What clearly stands out this quarter is the special items column, with a negative impact of EUR 12.71 per share, or roughly EUR 12.5 billion in absolute terms. That figure breaks down into EUR 10.8 billion for litigation and Crop Science, around EUR 1.3 billion for the Essure matter that Werner described, and EUR 0.4 billion for restructuring the related provisions.

Wolfgang Nickl

executive
#16

A positive tax effect of €1.97 is offsetting things to a small degree, and it also takes in the tax shield of around 15% that we mentioned on our litigation call at the end of June. All of this lands us at an EPS of minus €9.72 from continued and discontinued operations for the second quarter of 2020. Next, let's turn to our balance sheet. Net financial debt went up by roughly EUR 0.6 billion to about EUR 36 billion, compared with the close of last quarter. We redeemed our exchange of a bond for EUR 1 billion in cash, and we gained from a weaker US dollar, which had an effect of approximately EUR 0.5 billion. To give ourselves financial flexibility, we tapped the commercial paper market with tenor into the fall. As a reminder, our dividend payment of about EUR 2.8 billion was approved and executed during the quarter. Based on the recent publications from our rating agencies, we expect to keep our investment-grade rating. Lastly, please note that almost 60% of our financial debt is denominated in US dollars. The impact of exchange rate changes on our net financial debt is quite significant, since every percentage point of appreciation of the US dollar against the euro raises our net financial debt by about EUR 200 million, and vice versa.

Wolfgang Nickl

executive
#17

We keep tracking the COVID-19 factors that we laid out during our April investor call. Here is our current thinking on the rest of the year as it relates to the guidance we have updated. First — and it deserves repeating — safeguarding our employees' safety and well-being while keeping the business running continues to be our top priority. Second, although COVID-19 keeps pressing on our business, we are concentrating on what lies within our control, namely managing costs and managing cash flow. Along those lines, we are actively adjusting our flexible spending, such as travel and event expenses, and we are speeding up our efficiency initiatives. The crisis has driven considerable swings in currency markets. Using the Q2 rates, we anticipate a sizable adverse effect on our results over the remainder of the year. Consider the Brazilian real, which currently sits at roughly 6 Brazilian real per EUR versus the prior-year average of 4.41 Brazilian real per EUR. That works out to a 36% devaluation. Turning to our businesses, we anticipate that lower demand for corn-based bioethanol and grains this year will reduce acres planted in our key crops and therefore affect the expected sell-in for the 2021 growing season in the U.S.

Wolfgang Nickl

executive
#18

When it comes to our soybean business in the U.S., we anticipate that competitive pressure will persist. On the pharmaceuticals side, Werner has already noted the weaker demand, particularly across our IUD, ophthalmology, and radiology franchises. We look for that trend to turn around and improve sequentially in the quarters ahead. In Consumer Health, we expect the solid growth momentum to continue, and as a result, growth and earnings should come in better than we originally forecasted. With that as background, let's turn to our updated guidance. The first column of the chart shows the group guidance we gave in February for the full year at constant currencies. That guidance did not factor in the impact of the COVID-19 pandemic. Before we go further, I want to emphasize that the new outlook assumes we will not face a substantial second COVID-19 wave later this year. With that in mind, we now expect full year sales to decline by around EUR 1 billion, which translates into 0%-1% growth, adjusted for currency and portfolio effects. At the start of the year, our expectation had been growth of 3% to 4%. Approximately two-thirds of the negative COVID-19 impact comes from the Pharmaceuticals Division, while one-third is driven by Crop Science. As a result, for Pharmaceuticals we now expect slightly negative growth of approximately minus 1% currency and portfolio adjusted, including an anticipated milestone payment for Adempas toward the end of the year.

Wolfgang Nickl

executive
#19

On the Crop Science side, we’re now expecting growth of roughly 2% after adjusting for currency and portfolio effects. For Pharma, conditions should get better step by step through the remainder of the year, but when it comes to Crop Science, COVID-19’s hit is set to show up in full during the second half. Consumer Health got off to a good start this year, and we think COVID-19 will give that top line a small boost, which means the currency- and portfolio-adjusted growth rate for the year edges up slightly to about 4%. Even with those sales pressures, at group level we’re standing by our EBITDA margin before special items of approximately 28%. In Crop Science, we now project a somewhat lower EBITDA margin before special items, at 25%. For Pharma, our target sits between 34%-35%. In Consumer Health, we’re reaffirming the original margin target range of 22%-23%. On core EPS, we’re looking at an operational net decline of roughly €0.30. The sales shortfall and the gross profits tied to it are partly offset here by cost management, which includes a lower provision for variable compensation. Our free cash flow outlook takes a hit from the earnings reduction I mentioned and is further weighed down by expected settlement cash outflows of about €4.5 billion.

Wolfgang Nickl

executive
#20

Lower free cash flow likewise has a bearing on where we expect net financial debt to land at year-end. Net financial debt is also hit by movements in the fair value of our Elanco shares. In the third column you can see the revised guidance with currency effects stripped out. For sales, our currency-neutral guidance now sits at roughly €43 to €44 billion. The EBITDA margin before special items stays as it was, and core EPS would come in somewhere between €6.70 and €6.90. Free cash flow is expected to be between minus €0.5 billion and €0 billion, while net financial debt would be approximately €33 billion. The fourth column sets out what we anticipate currency will do to our full-year financials. Our calculation takes into account what has already been realized so far plus our forecast, which relies on June spot rates carried forward through the rest of the year. On full-year net sales, we foresee an adverse currency impact of about €1 billion, largely the result of the Brazilian real's devaluation, which mainly hits our Crop Science business during the second half. The footnote on the slide gives the assumed exchange rates for major currencies.

Wolfgang Nickl

executive
#21

In that final column you'll see our updated 2020 guidance, which factors in currency movements: sales expected between €42 billion and €43 billion, an EBITDA margin still at roughly 28%, and core EPS of €6.40 to €6.60. As for how currency swings affect free cash flow and net financial debt, those fall inside the rounded figures I gave a moment ago. I'd also point out that additional major KPIs appear in the appendix of our investor presentation. Before we open the Q&A, one thing worth stressing: even with pandemic-related headwinds, we anticipate core EPS will rise compared with last year, when it came in at €6.38. Delivering this ongoing record of core EPS growth is possible thanks to our sustained leadership in markets that are both highly relevant and resilient, along with a relentless emphasis on managing the factors we control. With that said, Oliver, I'll turn the call back to you so we can begin the Q&A.

Oliver Maier

executive
#22

Thanks. Wolfgang, thanks for that, and Werner, I appreciate your remarks. Before we get going, I want to flag something: as most of you probably are aware, we're planning an entirely virtual event centered on our Pharmaceuticals Division toward the end of this year — in all likelihood the beginning of December — where we'll address the mid- to long-term outlook for that business as well as our pipeline. Invitations should be sent out over the next few weeks, so consider that a heads up. On mid-term guidance, our present view is that we'll offer an update once we've closed out the 2020 financials. Now, on to the Q&A. As usual, I'd ask everyone to limit themselves to about 2 questions per person, which lets us field questions from as many participants as we can within the time available. With that, Emma, I believe we're ready to open the lines for the Q&A session.

Operator

operator
#23

Thanks. Ladies and gentlemen, we're going to start the question and answer portion at this time. Should you have a question, kindly press star then the one on your phone. To withdraw your request, press star then the two. If you're on speaker equipment today, please pick up the handset before making your selections. Please hold a moment for the first question. Our first question is from Mr. Vincent Andrews at Morgan Stanley. Please give your name, your company name, and then your question.

Vincent Andrews

analyst
#24

Hello there. Thanks. This is Vincent Andrews from Morgan Stanley. Morning to you all. Liam, to begin with what was discussed this quarter regarding returns in Brazil coming in above expectations, or above where they were a year earlier, might you provide a bit more detail on how large that was? I simply don’t remember it being a problem during the same period last year.

Liam Condon

executive
#25

Yes, absolutely. Thanks, Vincent. Two items tied to returns coming in better than expected — or what you might call returns phasing — gave us a positive lift in Q2 and then, you could say, were absent in Q3. The first was reduced product returns on fungicides in Brazil, and the second was a base effect from corn true-ups booked last year. As you'll remember, in Q2 we had the flooding, and at that point we set up provisions for higher returns. In the end, things turned out quite well and we reversed those provisions in Q3. Altogether, that effect landed in the ballpark — taken together, it came to roughly EUR 70 million.

Vincent Andrews

analyst
#26

So now your remarks about Q4 as it relates to next year's season—especially soybeans, where you're expecting more competition. That sounds like a hint that prices will fall further on the price cards coming out later this month. Maybe you could give us some color on that, and also on what your contingency plan is for Xtend next year in case you don't get re-registration for XtendFlex.

Liam Condon

executive
#27

Yes. Regarding soybeans, the reason we're indicating lower sales or lower sell-in in Q4 comes down to the fact that we're awaiting the new registration for XtendiMax. We expect it during Q4, though it depends heavily on exactly when in Q4 it arrives. Naturally, until the registration is granted, we aren't able to promote the product or make sales of it. That's the reason we have to stay somewhat cautious. Everything points to receiving the registration in Q4, but we simply don't know precisely when. Beyond that, as we move into the new year, the entire soybean market, as you're aware, is extremely dynamic and extremely competitive at present. We also intend to launch XtendFlex in the market next year, with plans for a launch across 20 million acres of soybeans. That will put us in a stronger position from a pricing standpoint too, since we'll then have an even more premium product available in the market. Our base assumption is quite clear: we will obtain the new registration in Q4, and we will launch XtendFlex to grow our overall market penetration next year.

Vincent Andrews

analyst
#28

Thanks.

Operator

operator
#29

We’ll now take the next question from Richard Vosser at J.P. Morgan. Please give your name and your company’s name, and then ask your question.

Richard Vosser

analyst
#30

Richard Vosser here from J.P. Morgan. Appreciate you taking my questions. I have two, please. Could you update us on where you stand with synergy realization and the efficiency program that were announced at the Capital Markets Day? I believe the total came to EUR 2.6 billion. How far along are you against that target? Along those lines, what additional savings have you captured so far this year from the absence of travel and similar items due to COVID-19? How much of those do you think you might be able to hold onto going forward? My second question is just thinking about your radiology franchises and some of the pharma franchises that COVID-19 affected in Q2. What are you seeing perhaps in June and July so far when it comes to the recovery? How should we think about those recovering and perhaps the recovery in EYLEA as well? Thanks very much.

Liam Condon

executive
#31

Alright, thank you.

Wolfgang Nickl

executive
#32

Yes. Richard, Wolfgang here. Thanks for the question. So, as I said in the prepared remarks, we're pulling out all the stops to speed up the measures across the various programs — whether that's the platforms, the synergy programs, or the programs in the other divisions. Originally, for the total group, we had targeted roughly 50% for the year, and that was already an upgrade versus what we told you a year earlier. Synergy realization is going very well. We had originally put that at something like 55%. We're now moving more toward 70% there. On the platform program as well, there are some things we can speed up and others we can't. We believe we'll be ahead of the game there too. On the whole, I'd expect this to land above 50%. Exactly what it will be is a bit too early to say. Yes, as you correctly point out, as a company we have travel and event costs in the several hundred millions. Of course, you couldn't save all of it in the first couple of months, because the travel restrictions came in around the March timeframe. Naturally, we had some cancellation fees, and so on. That will feed into the savings this year.

Wolfgang Nickl

executive
#33

On whether those savings will stick, it's a bit soon to make that call. I believe every company out there would say that the way we work is going to change from here on, with probably somewhat more happening virtually and somewhat less travel. It's a bit soon to quantify that. I'd also point out to you that a number of our costs are in fact going up. Specifically, if you look at logistics costs, we've seen fairly sizable increases there, including, for example, in our consumer business. There are always pluses and minuses, but as we go forward with forward guidance, we'll keep you posted on how sticky that turns out to be. Okay. Stefan?

Stefan Oelrich

executive
#34

Yeah. Hi, Richard. Where radiology is concerned, the second quarter proved rather difficult. Their procedure volumes dropped substantially, as you've noticed, with a modest uptick in June and additional gains in July. As we mentioned, we anticipate quarter-over-quarter gains in radiology across the year. Regarding EYLEA, things truly have been improving during the past month. At the start of the second quarter, that business was genuinely weak, and it too is getting better sequentially.

Wolfgang Nickl

executive
#35

All right, thank you, Stefan.

Richard Vosser

analyst
#36

Appreciate it.

Operator

operator
#37

Moving on, our next question is from Michael Leuchten at UBS. Please give your name and your company's name, then go ahead with your question.

Michael Leuchten

analyst
#38

Thank you. This is Michael Leuchten with UBS. I have two questions, please. First, perhaps for Wolfgang or maybe Werner: how should we think about how the first large tranche of settlement payments owed this year interacts with the uncertainty surrounding the future class and the judge's request for clarity on what a settlement process is? Is there an interaction? If so, what does it look like, or are the two entirely separate? My question for pharma, or on pharma: the 200 basis point increase in margin guidance compared with prior guidance — should we view that as sustainable, or are we really looking at the COVID benefits you just discussed, and then some of this will actually need to be given up as we think about 2021? Thank you.

Wolfgang Nickl

executive
#39

Alright, Michael, thank you for raising that question. Regarding how those pieces fit together, here is what I can share. Consistent with a comprehensive solution, we expect the EUR 4.5 billion figure we guided for this year. As I noted during my prepared remarks, we're putting substantial effort into getting both components of that comprehensive solution activated. I completely understand that not just you, but nearly everyone on this call would welcome additional detail on this. Right now we're in the midst of negotiations with representatives of the future class. We're also working, naturally, with Ken Feinberg, our court-appointed mediator, who is right in the middle of this and genuinely assists both sides, and who also serves as our channel to Judge Chhabria so a solution can be readied as fast as humanly possible and then presented back to the judge. Crucially, we have consistently stated that we don't wish to have an inventory solution without also having a future solution. That remains the goal, of course, even though those two matters are not contractually tied to one another. Yes. We have two distinct sets of agreements, but we are focused, and will stay focused, on a comprehensive solution that addresses both the inventory and the future.

Stefan Oelrich

executive
#40

This is Stefan. Hey, Michael. Appreciate you noting the improvement in our profile. We're happy about that as well, especially since we weren't able to fully hold the top line. We'll provide guidance early next year for 2021, so right now I can't really share the learnings for 2021, but I can assure you we're learning a great deal during this crisis about how to spend money.

Wolfgang Nickl

executive
#41

All right, thank you, Stefan.

Operator

operator
#42

Our next question is from Jo Walton at Credit Suisse. Kindly give us your name and your firm, then ask your question. Go right ahead.

Jo Walton

analyst
#43

Thank you. This is Jo Walton with Credit Suisse. Regarding the ag side, I'm curious whether you could share a bit more detail on those FieldView acres you have that are paid for, and what exactly the farmers are paying for. Is it genuinely high value-added services that will keep them tied to you, or is it still fairly low value-added services that you're essentially still giving away free in an effort to keep people involved? Turning to the pharma side, I wonder if you could provide a little more on NUBEQA and how that is starting to build, along with any thoughts on how it's launching in Europe. I understand it must be a virtual launch, and perhaps you have some pricing and early information you can give us.

Wolfgang Nickl

executive
#44

Alright, thanks, Jo. We'll start with Liam, and after that, Stefan.

Liam Condon

executive
#45

Thanks so much, Jo. On Climate FieldView, we're really pleased to have passed 110 million acres now — which, from a digital ag standpoint, is easily the deepest penetration anywhere in the world. As you know, with any platform business, market penetration comes first and foremost, and our initial pricing is set to drive that penetration, after which we gradually layer on additional products. That's the strategy overall. It's a combination: we charge farmers a per-acre price. We offer products directly to farmers, Seed Advisor being one example — advising on which seeds to plant, at what density, on which field, and giving them a clear picture of the yield they can expect from that. Naturally, we can leverage this data to enable our own business operations, essentially sharpening our own R&D and how we target customers. There are multiple benefits here, and as I said, we're very pleased that penetration remains very strong, mainly in the Americas, and we're now gradually beginning to roll it out in Europe as well.

Werner Baumann

executive
#46

All right, thank you, Liam. Over to you, Stefan?

Stefan Oelrich

executive
#47

Yes. Hello, Jo. Appreciate the question about NUBEQA. We remain extremely enthusiastic regarding how NUBEQA is progressing, though I have to admit that the COVID-19 crisis here in the U.S. has caused some delay in new patient starts, simply because fewer patients are walking into the office. Even so, when I look at the figures, they are improving sequentially month-over-month, even through this challenging period. Regarding Europe, you are completely correct. It is too soon to tell, but what I can share — I don't know whether you saw this yesterday — is that the G-BA issued its vote on the added benefit for NUBEQA, and it came out extremely positive. We are very pleased with how this is developing, and it foreshadows how reimbursement authorities in Europe are viewing this, and it aligns very much with what I have said from the start. Thank you.

Werner Baumann

executive
#48

Okay, thank you, Stefan.

Operator

operator
#49

Our following question is from Tony Jones at Redburn. Kindly give your name and your firm, then go ahead with what you'd like to ask.

Tony Jones

analyst
#50

Good afternoon, everyone. This is Tony Jones from Redburn. I appreciate you taking my questions. There are two — one for Wolfgang, one for Liam. First, regarding the EBITDA figure in Crop Science, could you give us some sense of the cost reduction amount for the quarter, simply by working backwards from the year-on-year absolute change and then making an adjustment for the volume gain? I understand that you typically don't discuss this each quarter. It seemed to matter quite a lot during this period. For Liam, could you say a little about how XtendFlex will be positioned on price next year? Is the plan to market it at a premium price in light of the enhanced tolerance, or does the strategy center on protecting market share, with price changing only minimally? Thank you.

Liam Condon

executive
#51

Sure, Tony — happy to take both questions, since they both bear heavily on Crop Science. Regarding the cost reduction in Q2, to give you a feel for how large that was for Crop Science and for our EBITDA results: the quarter's overall EBITDA increase came to roughly EUR 300 million, and cost reduction accounts for around half of that, split between accelerated cost synergies and what we'd just term additional savings tied to COVID and other items. We track these quite deliberately as distinct buckets, because we don't want them mixed together. There are our cost synergies, and then there are extra costs we hadn't originally planned for, but in the situation we're facing, we do see further opportunities. That should give you a sense of how much of the cost impact sits within the additional EBITDA delivered in Q2. As for XtendFlex, frankly, pricing is not yet settled. Naturally, we still need to get every registration finalized and have our final data in hand. You can infer from how we've handled the market before — if you consider our overall approach to Xtend within the soybean market — that we've been the leader on premium pricing.

Liam Condon

executive
#52

Our genetics are the strongest out there. So looking ahead, we think our extra trait package is very competitive as well. We'll stay on that course of establishing the benchmark in the market, purely because our products are premium.

Werner Baumann

executive
#53

Appreciate it, Liam.

Tony Jones

analyst
#54

Appreciate it.

Operator

operator
#55

Our following question is from Falko Friedrichs at Deutsche Bank. Kindly give your name and the firm you represent, then go ahead with your question.

Falko Friedrichs

analyst
#56

Thanks. This is Falko Friedrichs calling from Deutsche Bank, and I have two questions, please. First, regarding the Animal Health divestment, what tax impact should we expect on the proceeds from that divestment? Second, on the dicamba litigation, has an agreement been reached with BASF regarding how the payout will be split?

Wolfgang Nickl

executive
#57

Heiko, Wolfgang here. I'll handle the first question, and I believe Werner is covering the second. We've never broken this down by divestment, but let me give you a sense of the overall package. Across Animal Health, Currenta, and the businesses inside our Consumer Health unit, the total gross proceeds had headline values at the time of roughly €9.4 billion, and we stated the total tax effect comes to about €1 billion. That's a little over 10% on average across all of them. Since Animal Health is the largest, you can make your assumption that it will land in that same zip code as well.

Werner Baumann

executive
#58

Alright. Thank you, Wolfgang. Falko, regarding dicamba, we still haven't finalized an arrangement with BASF concerning the portion of costs they would be putting in. That remains something we need to complete over the coming month. Okay, thanks.

Operator

operator
#59

We’ll take our next question from Laurent Favre at Exane BNP Paribas. Please give your name and company name, then ask your question.

Laurent Favre

analyst
#60

Good afternoon. This is Laurent Favre calling from Exane, and I have two questions for Liam, if I may. Many thanks for walking us through the Q2 bridge detail. That naturally raises a question about the second half. Liam, could you explain a bit why margins would decline year-on-year in order to reach your full year EBITDA margin target? Is the main driver the Q4 effect on seeds along with mix, or is something else also at play — especially the uneven timing of cost savings that landed in Q2? My second question concerns LatAm a bit more. You spent a lot of time on the call discussing currency impact. I was wondering whether you could address pricing power and how you approach local pricing, covering seeds and crop protection separately. Thank you.

Liam Condon

executive
#61

Yeah. Okay. Many thanks, Laurent. Regarding the second half, when it comes to the margin decline, roughly three-quarters of that contraction is essentially tied to currency effects and the devaluation of the Brazilian real in Brazil. That represents the largest single hit to our EBITDA. The other quarter stems basically from weaker sales, and that's a combination of reduced sell-in of corn and soybeans in North America, which I brought up earlier, along with the absence of the favorable returns that, shall we say, worked in our favor during Q2 but are then absent in Q3 when making the year-over-year comparison. That, basically, accounts for what's happening. As was noted, overall we do have extra COVID-related costs, as you'd expect, from a hygiene standpoint and simply from a transportation and logistics standpoint. Those are largely offset by our synergies. That's mainly what's occurring on the EBITDA side during the second half. On currency, and this is specifically LatAm and chiefly Brazil. It's also, naturally, Argentina. LatAm accounts for the majority of our sales in the latter half of the year, and that's where our currency risk lies. We typically have several approaches for attempting to mitigate that risk, and normally this evens out.

Liam Condon

executive
#62

In Brazil, one thing worth noting is that the U.S. dollar serves as our functional currency, which gives us a fair degree of protection there. Our main difficulty is in Brazil, where crop protection accounts for three-quarters of the business, and pricing has to be done in local currency. Ultimately, at some point, those sales get translated into EUR. Any time the currency moves, we move quickly — or as quickly as we can — to revise our price lists and thereby offset that devaluation with new pricing. The difficulty arises when we accept pre-orders, say in the second quarter at one currency rate, and then record the sales only at a later rate, say in Q3 or Q4. At that moment, we must take whatever rate applies. Looking at where currencies stand now versus where they stood when we took some of those pre-orders, that is essentially the gap for this year, which our guidance reflects from a Forex standpoint. This will be captured in all future pricing lists. Those lists, of course, are adjusted right away and move higher, and we will make up for it afterward, though not within this year.

Liam Condon

executive
#63

That's the piece that will essentially hit us during this year. Beyond that, there's our corn seed production. A natural hedge exists for us since we grow corn locally at local currency rates. We use barter, which accounts for roughly 20%, 30% in Brazil and Argentina. On top of that, we have specific hedging policies in place. What we really need to manage is the pricing gaps in crop protection, along with any timing mismatches between pre-orders and booking sales.

Werner Baumann

executive
#64

All right, thanks, Liam.

Operator

operator
#65

Our following question comes from James Quigley at Morgan Stanley. Kindly give your name and your firm's name, then go ahead with your question.

James Quigley

analyst
#66

Hello, and thanks for taking my question. This is James Quigley with Morgan Stanley. I have a question about EYLEA. When you look at Lucentis, it declined 25% during the quarter. Is there something about EYLEA itself that has helped you capture share, rather than simply a lift from stocking tied to the pre-filled syringe? Second, a question about consumer. Clearly, some categories have enjoyed a substantial tailwind over the past couple of quarters. GSK recently ran a survey that seemed to indicate people value health more and are using vitamins more. What is the market showing you? What does your research indicate? Drawing on what you have observed historically, do you view this as sustainable, or might part of that benefit reverse over the coming couple of years? Thank you.

Werner Baumann

executive
#67

Alright, thank you, James. I’ll take Stefan next, and after that, Heiko, please.

Stefan Oelrich

executive
#68

Hello, James. Yeah, inside a very challenging market, we're quite happy that we're outperforming rivals in ophthalmology. It's difficult to guess why that is. Keep in mind that we launched the pre-filled syringe recently, and during the COVID crisis, stretching out a treatment regimen matters a great deal. Our treat and extend data, I believe, beats that of any other product in the category, along with its strong safety and tolerability profile. We're happy about that, and I hope it will be evident going forward too as total volume recovers.

Werner Baumann

executive
#69

All right, thank you, Stefan. Heiko, over to you?

Heiko Schipper

executive
#70

Sure, James. Let me share a little of how we’re thinking about the elements underneath this, obviously the stronger growth we’re seeing and what portion of it can last. Naturally, that’s difficult to pin down, and we’ll still need to get through the year to find out where we end up. When you look at our figures by category, obviously nutritionals stands out as a big contributor to the growth, and I believe that’s visible throughout the industry. Our sense is that, ultimately, COVID will cause self-care to receive more attention. People recognize they need to remain healthy and therefore have a reduced chance of catching viruses. In general, people are going to value healthcare more. If I split it out by category, nutritionals certainly is going to see, in my view, a positive effect that lasts. As for the remaining categories, we’ll have to wait and see. Certainly, many factors are having an influence right now. Of course, mask wearing is not helpful for the ordinary cough and cold business, nor for the allergy business, since when you spend a lot of time at home, obviously your allergy exposure will be lower. Overall, I’d say I think over the long term, there will be some positive effect.

Heiko Schipper

executive
#71

I think it's really too early to put a number on that, and the main focus there is on the nutritional side of the business.

Werner Baumann

executive
#72

Thanks, Heiko.

James Quigley

analyst
#73

Appreciate it.

Operator

operator
#74

Moving on to the next question, it comes from Keyur Parikh at Goldman Sachs. Please give your name and your company's name, and then ask your question.

Keyur Parikh

analyst
#75

Good afternoon, and thanks for taking my questions. I have two for Werner and one for Liam, please. Werner, just to clarify — if I heard you right, you said your midterm guidance also depends on, or could be affected by, the ongoing COVID-19 dynamics. Could you elaborate a bit on that, and how should we think about what that means for your midterm guidance? That's the first one. Second, in your opening remarks and in your answer to Michael's question about the settlement, you restated your preference for finding a solution that gives you certainty and visibility on both the existing cases and the potential for future litigation. Could you comment on your willingness to engage in something that resolves only the current litigation and does not resolve future litigation? Is that a no-go, or is it just reluctance? For Wolfgang — obviously it's too early to issue 2021 guidance, but I'm wondering, as you look at the shape or the consensus and expectations going into 2021, do you see them as fairly reflecting how you see the shape of the business? Thank you.

Werner Baumann

executive
#76

All right, thank you. We'll begin with Wolfgang on guidance, and after that we'll move to litigation — I'll handle that question — and then we'll shift over to Liam to answer the Crop question.

Wolfgang Nickl

executive
#77

Right. Very quickly — regarding the savings, I think we said part of that could potentially last. I have to say, it's a little early to be discussing midterm guidance. As Oliver mentioned during the intro remarks, we'll do that at the start of next year. There are many factors involved — COVID is one, FX is another, and now having divested all of the businesses is a third. We'll finish out this year, and then early next year we'll provide the midterm guidance.

Werner Baumann

executive
#78

All right, turning to the litigation now. As I said before, our stance has been — and still is — that we're aiming at a comprehensive solution. If you've been tracking this more closely, it's quite evident that Judge Chhabria strongly backs the inventory settlement, so that isn't where the problem lies. We're trying to find a way to resolve the four main concerns Judge Chhabria brought up in a new proposal, which we're negotiating over with the representatives of the futures class. We're optimistic, we keep making headway, and we'll see what these next weeks bring.

Liam Condon

executive
#79

Keyur, regarding the 20, if I got your question correctly, you're asking whether our view aligns with consensus for 2021 — whether that's roughly the right ballpark. Like Wolfgang said, we won't be discussing 2021 until later in the year. One point I'd like to make, since it ties to Q4 and, naturally, carries into 2021, is that what shapes our thinking is above all the COVID-19-related hit to biofuel demand, and along with that, to corn demand. Our calculations show that ethanol production in 2020 will be roughly 1.9 billion tons lower. That works out to around 680 million bushels of corn, or approximately 4 million acres of corn. Naturally, corn acres didn't decline this year — they actually rose by 1 million acres. That's the reason we're taking a cautious stance on our Q4 pre-purchasing outlook, since we believe an adjustment is needed there.

Werner Baumann

executive
#80

Alright, thanks, Liam.

Oliver Maier

executive
#81

All right, thank you all. Emma, I believe there’s room for one additional question.

Operator

operator
#82

Our last question is from Mr. Daniel Wendorff at Commerzbank. Kindly give us your name and the firm you represent, then ask your question.

Daniel Wendorff

analyst
#83

Yeah, thank you for taking my questions. This is Daniel Wendorff with Commerzbank, and I have two as well. The first one is a broader pharma question. Could you bring us up to date on what the key upcoming data readouts from your pharma pipeline are over the coming months? My second question is also about pharma, though perhaps a little more granular. What I'd really like to know is how VITRAKVI did in Q2, and how the launch is tracking versus what you expected — specifically, how smoothly the whole process involving the companion diagnostic test beforehand is actually working. Thank you.

Oliver Maier

executive
#84

Alright, thank you, Daniel. Over to you, Stefan.

Stefan Oelrich

executive
#85

Hi, Daniel. So on the news flow side, just to remind everyone, we've recently received two significant pieces of data. The first was the positive FIDELIO-DKD trial for finerenone, and that provides a route to registration, since one of our pivotal phase III studies came back positive on both the primary and secondary endpoints. That's really exciting. The second item, in terms of news flow, is that we've just been granted priority review for Vericiguat by the FDA, which highlights the value in an underserved patient population that the FDA recognizes. Looking ahead to the rest of this year and into next year, we of course anticipate the submission for finerenone following the positive FIDELIO-DKD results. We expect an approval for molidustat at some point down the road for Japan in renal anemia. Coming up for this year, in principle, in lymphoma patients, is the copanlisib data that should arrive for phase III. Next year we should see the second pivotal trial for finerenone, with the FIGARO data, which I believe will give us a very robust data package with two large phase III trials here. We're also very much looking forward to the ARASENS readout in darolutamide next year, where we should likewise have phase III, which will significantly, potentially expand the addressable patient population for this very, very interesting compound.

Oliver Maier

executive
#86

Regarding VITRAKVI?

Stefan Oelrich

executive
#87

VITRAKVI is a tricky one, since tracking is going as we expected. Even so, finding those patients remains a challenge for us. Throughout the COVID crisis, that situation hasn't really gotten better. It's a tough one. Perhaps it's occasionally a bit too sophisticated for physicians to diagnose patients properly. We aren't giving up. That's something we're actively working on.

Daniel Wendorff

analyst
#88

Yeah. Thanks.

Oliver Maier

executive
#89

Well, we're just about out of time, I think. There's one final question that came in by email — Peter Verdult at Citigroup couldn't ask it himself because of technical problems. Pete wants to know how excited we are about sharing the finerenone DKD data in October. He understands you can't talk about the data itself, but he's asking what your belief in it is, and how competitive it looks next to what the diabetic drug classes have produced, SGLT2 and the GLP-1s included.

Stefan Oelrich

executive
#90

I'll take that question. Hey, Pete, I hope you're able to hear us at least, even if you can't speak to us. Whenever you run a large cardiovascular outcome trial, you always have to be excited when the results come back positive, because there is so much riding on it, with so many patients enrolled and so much investment going into it. We're quite excited about this, since it gives us a pathway to approval in an area where I believe the patient population is very underserved. Even though there have lately been some options for DKD patients, the choice remains very much a limited one. We believe we offer something that other groups or other therapeutic choices may not. Having the first non-steroidal MRA in this area, I think, gives us confidence that we have a very valid option for patients. We'll see what happens with the second trial, but I think we have a pathway to submission and then hopefully to approval as well.

Oliver Maier

executive
#91

All right, wonderful. Thank you, Stefan. Appreciate it, Emma, and thanks to everyone, really, for making time and giving us your attention today. We truly value it, and Emma, I believe that brings our call to an end. Thank you.

Operator

operator
#92

That wraps up Bayer AG's investor and analyst call on the 2020 second-quarter results, everyone. We appreciate your joining us. You're free to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Bayer Aktiengesellschaft transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Bayer Aktiengesellschaft earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Bayer Aktiengesellschaft or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.